Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Eileen Regan"'
Autor:
Maria Moscvin, Christine Ivy Liacos, Tianzeng Chen, Foteini Theodorakakou, Despina Fotiou, Shahrier Hossain, Sean Rowell, Houry Leblebjian, Eileen Regan, Peter Czarnecki, Filippo Bagnoli, Niccolo’ Bolli, Paul Richardson, Helmut G. Rennke, Meletios A. Dimopoulos, Efstathios Kastritis, Giada Bianchi
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-7 (2023)
Abstract Thrombotic microangiopathy (TMA) has been reported to occur in multiple myeloma (MM) patients in association with treatment with carfilzomib, an irreversible proteasome inhibitor (PI). The hallmark of TMA is vascular endothelial damage leadi
Externí odkaz:
https://doaj.org/article/3db82b86263f49e39f4001b810e51940
Autor:
Jeffrey A Meyerhardt, Marek Ancukiewicz, Thomas A Abrams, Deborah Schrag, Peter C Enzinger, Jennifer A Chan, Matthew H Kulke, Brian M Wolpin, Michael Goldstein, Lawrence Blaszkowsky, Andrew X Zhu, Meaghan Elliott, Eileen Regan, Rakesh K Jain, Dan G Duda
Publikováno v:
PLoS ONE, Vol 7, Iss 6, p e38231 (2012)
To determine the maximum tolerated dose (MTD) and safety, and explore efficacy and biomarkers of vandetanib with cetuximab and irinotecan in second-line metastatic colorectal cancer.Vandetanib (an orally bioavailable VEGFR-2 and EGFR tyrosine kinases
Externí odkaz:
https://doaj.org/article/be6eb12b430845b7bbb31be9b632a516
Autor:
Dan G. Duda, Rakesh K. Jain, David P. Ryan, Charles S. Fuchs, Michelle Knowles, Eamala Vasudev, Eileen Regan, Susan Sheehan, Alona Muzikansky, Pankaj Bhargava, Nadine Jackson McCleary, Thomas A. Abrams, Jeffrey A. Meyerhardt, Lawrence S. Blaszkowsky, Dushyant V. Sahani, Jeffrey G. Supko, Marek Ancukiewicz, Andrew X. Zhu
Purpose: We conducted a single-arm phase II study of cediranib, a pan-VEGFR tyrosine kinase inhibitor, in patients with advanced hepatocellular carcinoma (HCC).Experimental Design: Patients with histologically confirmed measurable advanced HCC and ad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7160077e35660095c7827d46ac4afdae
https://doi.org/10.1158/1078-0432.c.6522066.v1
https://doi.org/10.1158/1078-0432.c.6522066.v1
Autor:
Dan G. Duda, Rakesh K. Jain, David P. Ryan, Charles S. Fuchs, Michelle Knowles, Eamala Vasudev, Eileen Regan, Susan Sheehan, Alona Muzikansky, Pankaj Bhargava, Nadine Jackson McCleary, Thomas A. Abrams, Jeffrey A. Meyerhardt, Lawrence S. Blaszkowsky, Dushyant V. Sahani, Jeffrey G. Supko, Marek Ancukiewicz, Andrew X. Zhu
PDF file - 159K, Supplementary Table S1: Kinetics of plasma biomarkers and circulating progenitor cells (CPCs) at days 1 and/or 14 during the first cycle of daily 30mg cediranib monotherapy in advanced HCC patients. Supplementary Table S2: Analysis o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::231bc451c192c12945b6390a090af423
https://doi.org/10.1158/1078-0432.22450974
https://doi.org/10.1158/1078-0432.22450974
Autor:
Andrew X. Zhu, Dan G. Duda, Rakesh K. Jain, Kohei Shigeta, Emilie Mamessier, Tai Hato, Eileen Regan, Caroline F. Dinicola, Anthony J. Afflitto, Aralee Galway, Michelle Knowles, Alona Muzikansky, Avinash Kambadakone, Jeffrey W. Clark, Matthew B. Yurgelun, Jill N. Allen, Andrea J. Bullock, Rebecca Miksad, Thomas A. Abrams, Hui Zheng, Lipika Goyal
Figure S1 is a schematic of lymphocytes shown as CD3+ cells against side scatter (SSC). Figure S2 is a Kaplan-Meier time-to-progression graph.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4aac09adb55eeb2866688064160541dc
https://doi.org/10.1158/1078-0432.22474422
https://doi.org/10.1158/1078-0432.22474422
Autor:
Andrew X. Zhu, Dan G. Duda, Rakesh K. Jain, Kohei Shigeta, Emilie Mamessier, Tai Hato, Eileen Regan, Caroline F. Dinicola, Anthony J. Afflitto, Aralee Galway, Michelle Knowles, Alona Muzikansky, Avinash Kambadakone, Jeffrey W. Clark, Matthew B. Yurgelun, Jill N. Allen, Andrea J. Bullock, Rebecca Miksad, Thomas A. Abrams, Hui Zheng, Lipika Goyal
Purpose:Sorafenib is a standard first-line treatment for advanced hepatocellular carcinoma (HCC). The phase III SHARP trial showed a median time-to-progression (mTTP) of 5.5 months, overall response rate (ORR) of 2%, and median overall survival (mOS)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae7e2b43bbbedb01a8b5b498b8558469
https://doi.org/10.1158/1078-0432.c.6528783
https://doi.org/10.1158/1078-0432.c.6528783
Autor:
Kimberly Perez, Matthew H. Kulke, Nora K. Horick, Eileen Regan, Christopher Graham, Samantha Scheutz, Danielle Stonely, Peter C. Enzinger, Charles S. Fuchs, Jill N. Allen, Andrea C. Enzinger, Jeffrey W. Clark, Jennifer A. Chan
Publikováno v:
Pancreas. 51(7)
Neuroendocrine tumors (NETs) are characterized by their expression of vascular endothelial growth factor (VEGF). This trial investigated the activity of Ziv-aflibercept, a recombinant protein that binds to and inhibits the activity of VEGF, in patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d52c655daf67db8a4464c9487491251
https://pubmed.ncbi.nlm.nih.gov/36395401
https://pubmed.ncbi.nlm.nih.gov/36395401
Autor:
Anthony James Afflitto, Lipika Goyal, Emilie Mamessier, Jeffrey W. Clark, Rakesh K. Jain, Hui Zheng, Michelle Knowles, Rebecca A. Miksad, Jill N. Allen, Andrew X. Zhu, Alona Muzikansky, Caroline Dinicola, Matthew B. Yurgelun, Aralee Galway, Eileen Regan, Tai Hato, Dan G. Duda, Thomas A. Abrams, Andrea J. Bullock, Kohei Shigeta, Avinash Kambadakone
Publikováno v:
Clinical Cancer Research
Clinical Cancer Research, 2019, 25 (1), pp.80-89. ⟨10.1158/1078-0432.CCR-18-0847⟩
Clinical Cancer Research, 2019, 25 (1), pp.80-89. ⟨10.1158/1078-0432.CCR-18-0847⟩
Purpose: Sorafenib is a standard first-line treatment for advanced hepatocellular carcinoma (HCC). The phase III SHARP trial showed a median time-to-progression (mTTP) of 5.5 months, overall response rate (ORR) of 2%, and median overall survival (mOS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d474b5da90d04a8d715140563e3a95d
https://doi.org/10.1158/1078-0432.ccr-18-0847
https://doi.org/10.1158/1078-0432.ccr-18-0847
Autor:
Christine Liacos, Paul G. Richardson, Foteini Theodorakakou, Efstathios Kastritis, Eileen Regan, Despina Fotiou, Maria Moscvin, Tianzeng Chen, Giada Bianchi, Meletios A. Dimopoulos
Publikováno v:
Blood. 138:2708-2708
Introduction Vascular endothelial injury related to treatment with proteasome inhibitors (PI) has been previously described. Carfilzomib is an irreversible PI and has been associated with cardiovascular toxicity, suggesting increased risk of endothel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c00ff57bdd8a4e06dcc56fdd344dba73
https://doi.org/10.1182/blood-2021-153229
https://doi.org/10.1182/blood-2021-153229
Autor:
Rakesh K. Jain, Lipika Goyal, James M. Cleary, Darrell R. Borger, Dan G. Duda, Matthew B. Yurgelun, Andrew X. Zhu, Jill N. Allen, Eileen Regan, Valentina Nardi, Thomas A. Abrams, Amanda Reardon, Anna Khachatryan, Hui Zheng, Michelle Knowles
Publikováno v:
Cancer. 123:1979-1988
BACKGROUND Advanced cholangiocarcinoma carries a poor prognosis, and no standard treatment exists beyond first-line gemcitabine/platinum-based chemotherapy. A single-arm, phase 2 and biomarker study of cabozantinib, a multikinase inhibitor with poten
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6900ad52ba4cdca5f819abb0dd1c3751
https://doi.org/10.1002/cncr.30571
https://doi.org/10.1002/cncr.30571